University of California

Chiron Corporation

Novartis Vaccines & Diagnostics, Gmbh

Other

Sirna Therapeutics, Inc.

Cor Therapeutics, Inc.

Nuvelo, Inc.

Ribozyme Pharmaceuticals, Incorporated

Jaime A Escobedo

Lewis T Williams

Pablo Dominguez Garcia

James A McSwiggen

Giulia C Kennedy

Christoph Reinhard

Filippo M Randazzo

Pamela Pavco

George Lamson

Julie Sudduth-Klinger

David Lawrence Wolf

Klaus Giese

Neill A Giese

Larry J Fretto

James E Tomlinson

Radoje Drmanac

Dan T Stinchcomb

Snezana Drmanac

Michael A Innis

David B Kita

James Mcswiggen

Joerg Kaufmann

Vivien W Chan

David Pot

Ivan Labat

Varavani J Dwarki

Altaf Kassam

Birgit Stache-Crain

Rhonda Hansen

Mark Dickson

Shang-Zhen Zhou

Daniel Stinchcomb

Lee William Jones

Veronica Garcia

Dena Leshkowitz

Radomir Crkvenjakov

Edward J Moler

Martha B Ladner

Stephen F Hardy

Mervin C Yoder

Arun Srivastava

Selvarangan Ponnazhagan

Xu-Shan Wang

Robert H Chloemer

Dan T Stinchomb

The present invention provides polynucleotides, as well as polypeptides encoded thereby, that are differentially expressed in cancer cells. These polynucleotides are useful in a variety of diagnostic and therapeutic methods. The present invention further provides methods of reducing growth of cancer cells. These methods are useful for treating cancer.

Gene products differentially expressed in cancerous cells

Human endogenous retroviruses of the HML-2 family show up-regulated expression in prostate tumors. This finding can be used in prostate cancer screening, diagnosis and therapy.

Endogenous retroviruses up-regulated in prostate cancer

This invention relates to novel human polynucleotides and variants thereof, their encoded polypeptides and variants thereof, to genes corresponding to these polynucleotides and to proteins expressed by the genes. The invention also relates to diagnostic and therapeutic agents employing such novel human polynucleotides, their corresponding genes or gene products, e.g., these genes and proteins, including probes, antisense constructs, and antibodies.

Human genes and gene expression products V

DNA sequences encoding human platelet-derived growth factor receptors (hPDGF-R), and expression constructs comprising sequences which encode a receptor that can be secreted or incorporated into the membrane of a mammalian cell. Peptide fragments with functions equivalent to the wild-type receptor, conferring a PDGF-sensitive mitogenic response on cells lacking the receptor are provided. The constructs can be used for enhancing PDGF response of cells, determining the regions involved in transducing the signal in response to PDGF binding, providing mutated analogs and evaluating drugs for their physiologic activity. Soluble fragments comprising PDGF receptor sequences are also provided, including important intracellular kinase insert sequences which interact with intracellular proteins.

Human platelet-derived growth factor receptors

The present invention relates to nucleic acid molecules such as ribozymes, DNAzymes, and antisense which modulate the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor, such as flt-1 and KDR. Nucleic acid molecules and methods for the inhibition of angiogenesis and treatment of cancer and ocular diseases are provided, optionally in conjunction with other therapeutic agents.

Enzymatic nucleic acid-mediated treatment of ocular diseases or conditions related to levels of vascular endothelial growth factor receptor (VEGF-R)

Human genes and gene expression products II

The present invention relates to nucleic acid molecules which modulate the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor.

Method and reagent for the treatment of diseases or conditions related to levels of vascular endothelial growth factor receptor

Platelet-derived growth factor receptors

A DNA sequence encoding human platelet-derived growth factor receptor (hPDGF-R) has now been isolated and sequenced. An expression construct comprising the sequence encodes a receptor that can be secreted or incorporated into the membrane of a mammalian cell. The incorporated receptor is functionally equivalent to the wild-type receptor, conferring a PDGF-sensitive mitogenic response on cells lacking the receptor. The construct can be used for enhancing PDGF response of cells, determining the regions involved in transducing the signal in response to PDGF binding, providing mutated analogs and evaluating drugs for their physiologic activity.

Methods for detecting human platelet-derived growth factor receptor agonists and antagonists

The present invention is directed to a recombinant adenovirus vector comprising two inverted terminal repeats (ITRs) each of which comprises a D-sequence having (i) from 5 to 15 native nucleotides and (ii) one or more deletions or substitutions therein.

AAV vectors

Human platelet-derived growth factor receptor

Nucleic acid molecule which modulates the synthesis, expression and/or stability of an mRNA encoding one or more receptors of vascular endothelial growth factor.

Growing community of inventors

San Francisco, CA, United States of America

Jaime A Escobedo